Scientists from SRI International and Collaborations Pharmaceuticals in the US have identified a potential new inhibitor, tilorone dihydrochloride, for infection by Ebola virus.

The researchers used machine learning methods to find the immunomodulatory drug, which is reported to have demonstrated significant efficacy with 100% survival in a disease model of the virus.

Tilorone is currently used in Russia for the treatment of various infections such as influenza, acute respiratory viral infection, viral hepatitis, myelitis and viral encephalitis.

The identification of this low-molecular weight drug is said to offer a new mechanism of action and broad-spectrum activities for the Ebola infection.

With a combination of anti-Ebola efficacy and safe history of usage in humans, tilorone is expected to be an ideal product candidate for development as a monotherapy or combination therapy in the future.

“Tilorone has the clear advantages of widespread availability, broad-spectrum antiviral potential and a track record of safe human use for other viral diseases.”

Collaborations Pharmaceuticals CEO Sean Ekins said: “Tilorone was one of three molecules that had been previously identified using a Bayesian Machine learning model and found to be active in-vitro against the Ebola virus, and now represents the first of these to be tested in-vivo.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“This work was based on an initial high throughput screen published by SRI International and demonstrates how such data can be used to help develop new drugs.”

SRI International Discovery Technologies director Peter Madrid said that additional preclinical assessments and disease models will be used to gain better understanding of the compound.

Madrid added: “Tilorone has the clear advantages of widespread availability, broad-spectrum antiviral potential and a track record of safe human use for other viral diseases.”